Core Insights - Cibus is focusing on the commercialization of Rice herbicide tolerance traits HT1 and HT3, with initial launches planned in Latin America in 2027 and the U.S. in 2028, potentially generating over $200 million in annual royalties [1][2][3] - The company aims to reduce annual cash usage to approximately $30 million by 2026 through operational streamlining [1][2] - Cibus raised $27.5 million in gross proceeds from a public offering, extending its cash runway as it approaches initial revenue generation [1][10] Financial Performance - For the quarter ended June 30, 2025, Cibus reported a net loss of $26.6 million, compared to a net loss of $28.5 million in the same period last year [20][27] - Revenue for the quarter was $933,000, an increase from $838,000 year-over-year [27] - Research and development expenses decreased to $12.2 million from $13.0 million, while selling, general, and administrative expenses fell to $6.6 million from $9.3 million, primarily due to cost reduction initiatives [13][27] Operational Updates - Cibus has signed a collaboration agreement with Colombian Rice producer Semillano and completed the delivery of three germplasm lines with the Cibus HT3 trait to an existing customer [1][3] - The company is on track for nominal revenues from its sustainable ingredients program in 2025, with targeted commercial expansion planned for 2026 [1][5][7] - The global regulatory environment for gene editing technologies remains supportive, with positive developments in various markets including the EU, Ecuador, India, and the U.S. [1][4][7] Strategic Focus - Cibus is concentrating on its core priorities: advancing Rice herbicide tolerance traits and partner-funded sustainable ingredients programs [2][3] - The company is expanding its trait pipeline and exploring additional opportunities for partner-funded programs [5][6] - Cibus is committed to operational efficiencies and building a foundation for sustainable growth to generate long-term shareholder value [2][3]

Core Insights - Profound Medical Corp. reported its second quarter financial results for 2025, highlighting growth in TULSA-PRO system utilization and a strong sales pipeline, despite experiencing short-term delays in capital sales [1][3]. Business Highlights - Utilization of TULSA-PRO systems increased, with "same store" procedure volumes rising by 10% sequentially from Q1-2025 [2]. - The sales pipeline for TULSA-PRO has expanded to 80 new systems in various stages of the sales process [2]. - Patient demographics treated with TULSA-PRO in Q2-2025 included 79% for prostate cancer, 17% for hybrid conditions, and 3% for salvage therapy [2]. - The company hosted an investor event at the AUA 2025, showcasing positive initial data from the CAPTAIN trial, which indicated TULSA's advantages over robotic radical prostatectomy [2]. - Leonard Wheeler was appointed as Global Ambassador for TULSA-PRO to enhance awareness and advocacy [2]. - The TULSA-AI Volume Reduction Module was successfully launched for BPH treatment, with a full launch expected in Q4-2025 [3]. Financial Performance - Revenue for Q2-2025 was approximately $2.2 million, with $1.6 million from recurring non-capital revenue and $650,000 from capital equipment sales [4]. - Gross margin improved to 73% in Q2-2025, up from 64% in the prior year, attributed to higher manufacturing efficiency [5]. - Total operating expenses rose to approximately $15.4 million, compared to $9.3 million in the previous year, driven by increased headcount and trial enrollment [6]. - The net loss for Q2-2025 was approximately $15.7 million, or $0.52 per share, compared to a loss of $6.9 million, or $0.28 per share, in Q2-2024 [7]. Liquidity and Share Capital - As of June 30, 2025, the company had cash reserves of approximately $35.2 million [8]. - The total number of common shares outstanding was 30,053,142 as of August 14, 2025 [8].

Second Quarter 2025 Revenues Totaled $3.3 Million, Driven by Continued Industry Recognition of Intellectual Property Portfolio CORSICANA, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Birchtech Corp. (TSX: BCHT) (OTCQB: BCHT) ("Birchtech" or the "Company"), a leader in specialty activated carbon technologies for sustainable air and water treatment, today reported financial results for the second quarter ended June 30, 2025. Key Second Quarter 2025 & Subsequent Operational Highlights Pending final judgment follo ...

Core Insights - CapsoVision, Inc. reported a total revenue of $3.3 million for Q2 2025, marking a 17% increase compared to Q2 2024, primarily driven by increased sales of CapsoCam Plus capsules [6][9] - The company successfully completed its IPO in July 2025, raising net proceeds of approximately $23.4 million, which will be used to accelerate growth and expand into new indications [3][7][9] - Management highlighted the importance of obtaining FDA 510(k) approval for the AI module in CapsoCam Plus and the continued development of CapsoCam Colon as key growth drivers [4][5] Financial Performance - Total revenue for Q2 2025 was $3.3 million, a 17% increase from $2.8 million in Q2 2024 [6][14] - Gross profit increased to $1.8 million, up 14% from $1.6 million in Q2 2024, with a gross margin of 55% [6][14] - Operating expenses decreased to $6.5 million, down $0.4 million from Q2 2024, mainly due to reduced expenses related to clinical trials [7][14] Operational Highlights - New accounts grew by 75% in Q2 2025 compared to the same quarter in 2024 [9] - CapsoCam Plus has been utilized by over 143,000 patients as of June 30, 2025 [9] - The company submitted a 510(k) notification to the FDA for CapsoCam Colon in June 2025 [9] Future Outlook - The company aims to enhance accuracy and ease physician workload through the integration of AI in its products [4] - CapsoVision plans to advance programs targeting pancreatic cancer and esophageal varices, leveraging its panoramic imaging technology [4][5]

Financial Results - For Q2 2025, net sales were $1,031,000, a decrease from $3,013,000 in Q2 2024, reflecting a decline in product sales due to deferred capital expenditures by customers [5][22] - For the first half of 2025, net sales were $2,608,000, down from $4,127,000 in the same period of 2024 [5][22] - Gross profit margin improved to 66% in Q2 2025, compared to 62% in Q2 2024, attributed to a favorable product mix [5][22] - The company reported an operating loss of $(1,133,000) for Q2 2025, compared to an income of $122,000 in Q2 2024 [5][22] - Net loss for Q2 2025 was $(1,238,000) or $(0.06) per share, compared to a net income of $30,000 or $0.00 per share in Q2 2024 [5][22] Business Highlights - Service and training revenue increased by 33% year-over-year in Q2 2025 and by 46% in the first half of 2025, indicating strong demand for decontamination services [5][6] - SteraMist solution sales rose by 40% year-over-year for the first half of 2025 [5] - The company achieved nearly 20% of Q2 revenue from international markets, demonstrating ongoing global expansion [5][6] Strategic Initiatives - The company is focused on expanding recurring service contracts and exploring new product lines to generate steady income [12] - Plans to strengthen the corporate team and expand talent in key areas such as sales and customer support are underway [9] - The company is negotiating approximately $2 million in new custom and integrated contracts, with bids expected to close before year-end [5] Leadership and Recognition - David Vanston was appointed as Chief Financial Officer in May 2025, bringing extensive experience to support growth and capital strategy [7] - The company received the "Disinfection and Decontamination Products Company of the Year" award by MedTech Outlook in June 2025, highlighting its commitment to excellence [6] Liquidity and Capital Access - As of June 30, 2025, the company had working capital of $2.8 million, with cash used in operations improving by over $1 million compared to the prior year [8] - The company completed a $435,000 convertible note financing in the first half of 2025 to support growth initiatives [8]

Core Viewpoint - Glucotrack, Inc. is making significant advancements in the development of its fully implantable continuous blood glucose monitor (CBGM) system, with plans to initiate clinical studies in Australia and submit an Investigational Device Exemption (IDE) to the FDA by the end of 2025, while also strengthening its corporate structure and expanding its advisory boards [1][2][11]. Corporate Highlights - The company is on track to implant the first patients in a long-term, multicenter feasibility study of the CBGM system in Australia in Q3 2025 [1]. - An IDE submission to the FDA for the novel CBGM technology is anticipated in Q4 2025 [1]. - The Board of Directors has been strengthened with the appointment of Dr. David S. Hirsh as Medical Director - Cardiology and Dr. Victoria E. Carr-Brendel to the Board [2][5]. - A Patient Advisory Board has been established to incorporate patient perspectives into the development of the CBGM technology [2][5]. Financial Overview - Cash and cash equivalents as of June 30, 2025, were $9.6 million, an increase from $5.6 million as of December 31, 2024, primarily due to $10.7 million in net proceeds from public equity financings [12]. - Research and development expenses for the six months ended June 30, 2025, were $5.0 million, down from $5.7 million in the prior-year period [8]. - Marketing, general, and administrative expenses increased to $3.3 million for the six months ended June 30, 2025, compared to $1.7 million in the prior-year period [9]. - The net loss for the six months ended June 30, 2025, was $11.6 million, compared to a net loss of $7.4 million for the same period in the previous year [10]. Clinical Development - Positive results were reported from a first-in-human study for the CBGM, achieving a Mean Absolute Relative Difference (MARD) of 7.7% across 122 matched pairs, with a 99% data capture rate [11]. - The company received ethical approval in Australia to initiate a long-term clinical study of the CBGM in participants with type 1 and type 2 diabetes [11]. - Glucotrack is participating in the FORGETDIABETES initiative, which aims to develop an artificial pancreas for type 1 diabetes, utilizing the CBGM technology for real-time glucose data [11].

Core Insights - Dragonfly Energy Holdings Corp. reported a strong second quarter with net sales increasing by 23% year-over-year, driven by a 50.6% growth in OEM sales despite economic uncertainties [2][4][6] - The company is focused on optimizing its operations and strengthening its balance sheet, which includes the recent exchange of preferred shares and a public offering to enhance financial flexibility [2][5][9] - For the third quarter, the company anticipates net sales of approximately $15.9 million, representing a projected 25% year-over-year increase [9][10] Financial Highlights - Net sales for the second quarter of 2025 were $16.2 million, compared to $13.2 million in the prior year, marking a 23% increase [4][6] - OEM sales reached $10.1 million, up from $6.7 million, while DTC sales decreased by 9% to $5.9 million due to macroeconomic pressures [4][6] - Gross profit increased by 45.4% to $4.6 million, with a gross margin expansion of 430 basis points to 28.3% [5][6] - Operating expenses decreased to $7.9 million from $9.9 million, primarily due to lower R&D costs [5][6] Loss and Adjusted EBITDA - The company reported a net loss of $(7.0) million, an improvement from a net loss of $(13.6) million in the previous year [7][28] - Adjusted EBITDA was $(2.2) million, compared to $(6.2) million in the prior year, indicating improved operational performance [6][7] Strategic Outlook - The company emphasizes the effectiveness of its strategic initiatives and the sustained market demand for its energy storage solutions [9] - Dragonfly Energy is well-positioned for continued growth, supported by deepening customer relationships and operational efficiency [9]

Core Viewpoint - NANO Nuclear Energy Inc. is positioned to capitalize on the growing demand for clean and reliable nuclear energy solutions, driven by regulatory support and advancements in technology, particularly through its KRONOS MMR Energy System [2][11]. Financial Results - The company reported a cash and cash equivalents balance of $210.2 million as of June 30, 2025, a significant increase from $28.5 million on September 30, 2024, due to successful capital raises [9]. - Operating activities resulted in a cash outflow of $14.7 million for the nine months ended June 30, 2025, primarily due to increased operations and R&D expenses [3]. - Investing activities accounted for a cash outflow of $12.9 million, including $9.1 million for the acquisition of assets like the KRONOS MMR [4]. - Financing activities provided a net cash inflow of $209.3 million during the same period [5]. Technological Advancements & Regulatory Progress - The KRONOS MMR is advancing towards licensing and deployment in the U.S., with significant progress made in collaboration with the University of Illinois Urbana-Champaign [9][11]. - The company has received an approved Fuel Qualification Methodology Topical Report from the NRC and is focused on resuming licensing activities in Canada [9][11]. - NANO Nuclear aims to be the first commercial microreactor company in the U.S. to file for a construction permit application by late 2025 or early 2026 [11][12]. Operational Progress & Leadership - NANO Nuclear has made key appointments to its leadership team, including Rick Perry as Chairman of the Executive Advisory Board and Seth Berl as an independent director, enhancing its strategic capabilities [10][13]. - The company has initiated a recruitment drive to expand its engineering and project development teams, successfully hiring over a dozen engineers [13]. Strategic Collaborations & Market Position - NANO Nuclear signed a Memorandum of Understanding (MOU) with UrAmerica to secure resources and enhance its nuclear fuel supply chain [10]. - The company has been selected for inclusion in the Solactive Global Uranium & Nuclear Components Total Return Index, qualifying it for the Global X Uranium ETF, which enhances its market visibility [10][12]. - NANO Nuclear is exploring opportunities for vertical integration through collaborations and potential mergers and acquisitions to strengthen its competitive position [11][12].

GTB-3650 TriKE® Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2’s formal safety review, it has advanced into Cohort 3 and initiated dosing of the fifth patient in the study; initial Phase 1 data expected later in 2025GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors expected in Q4 2025; recent peer-reviewed publication highlights the pre-clinical anti-tumor activity of GTB-5550 against head and neck cancer ...

Core Insights - Bolt Biotherapeutics is advancing its clinical-stage immunotherapy pipeline, particularly focusing on BDC-4182, a next-generation Boltbody™ ISAC targeting claudin 18.2, currently in a Phase 1 dose-escalation study for gastric and gastroesophageal cancer [2][6][9] - The company reported a cash balance of $48.5 million as of June 30, 2025, which is expected to fund key milestones through mid-2026 [5][6] - Collaboration revenue for the second quarter of 2025 was $1.8 million, an increase from $1.3 million in the same quarter of 2024, indicating growth in R&D collaborations [6][11] Business Update - The Phase 1 study for BDC-4182 opened for enrollment in early 2025, with initial data expected in the first half of 2026 [2][6] - The company is seeking a partner for the further development of BDC-3042, which has shown activity in lung cancer patients [2][6] - Collaborations with Genmab and Toray are progressing, focusing on multiple development candidates and research programs [6][9] Financial Results - Total collaboration revenue for the quarter ended June 30, 2025, was $1.8 million, compared to $1.3 million for the same quarter in 2024 [6][11] - Research and Development (R&D) expenses decreased to $7.5 million in Q2 2025 from $15.4 million in Q2 2024, primarily due to reduced salary and clinical expenses [6][11] - General and Administrative (G&A) expenses also decreased to $3.5 million in Q2 2025 from $4.9 million in Q2 2024, reflecting cost management efforts [6][11] Operational Highlights - The company executed a one-for-twenty reverse stock split on June 6, 2025, which helped regain compliance with Nasdaq's minimum bid price requirement [7] - The Boltbody™ ISAC platform combines tumor-targeting antibodies with immune stimulants to enhance anti-cancer responses [8][9] - The company’s pipeline includes BDC-4182 and BDC-3042, with ongoing efforts to establish partnerships for further development [9]